RxDoctor Payments Data

Ven Kottapalli, MD

Gastroenterology · Lima, OHNPI 1144288408

Payments from drug & device makers

$19,506in general payments, 2019–2025

Across 854 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$7K
  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$717
  • Merck$577
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$12,30363%
  • Education$680%
  • Other$7,13537%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,506 in reported general payments places this provider in the 75th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$232,019
Medicare patients
601
Services billed
3,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide12$550,420
RinvoqUpadacitinib20$121,071
XifaxanRifaximin26$82,867
Budesonide ErBudesonide46$61,502
LinzessLinaclotide54$54,650
Mesalamine28$21,724
Mesalamine ErMesalamine18$9,762
Pantoprazole Sodium572$6,707
Famotidine431$4,603
Mesalamine DrMesalamine13$3,553
Dexlansoprazole DrDexlansoprazole17$2,516
Azathioprine14$1,655
Omeprazole157$1,644
CholestyramineCholestyramine (With Sugar)17$1,345
LoperamideLoperamide Hcl21$942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$2,034$550,42012 claims
AbbVieRinvoq, Linzess$3,360$175,72074 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,384$82,86726 claims
SandozLansoprazole$37$71816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →